Wuhan Ruisheng Pharmaceutical

Wuhan Ruisheng Pharmaceutical is a China-based pharmaceutical manufacturing company focused on generic drug R&D, active pharmaceutical ingredient production, intermediates, excipients, and related CDMO services. The company appears to be the entity commonly referred to in English-language trade directories as "Wuhan ZY Pharmaceutical," while its Chinese corporate name is 武汉瑞晟药业有限公司. It operates a manufacturing base in the Gedian Economic and Technological Development Zone in Ezhou, Hubei, and is part of the QR/启瑞 group ecosystem. The business emphasizes export-oriented API manufacturing aligned with cGMP/FDA standards and has marketed or registered products including atorvastatin calcium, fasudil mesylate, sofalcone, voriconazole, posaconazole, and sulfobutyl betadex sodium. Publicly visible evidence indicates the company is primarily a commercial-stage API and pharmaceutical intermediates manufacturer rather than a venture-backed clinical biotech with a disclosed novel-drug pipeline.